Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Pancreatitis I: Introduction01:25

Acute Pancreatitis I: Introduction

Acute pancreatitis is the sudden inflammation of the pancreas caused by the early activation of digestive enzymes, leading to the autodigestion of pancreatic tissue. This results in local inflammation and, in severe cases, systemic complications.EtiologyUnderstanding the underlying causes is crucial, as identifying the etiology guides treatment and anticipates complications. Acute pancreatitis can be triggered by various factors, typically grouped into the following clinical categories.Biliary...
Acute Pancreatitis I: Introduction01:27

Acute Pancreatitis I: Introduction

Pancreatitis is inflammation of the pancreas, an organ located behind the stomach. It can be either acute or chronic.
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
Acute Pancreatitis II: Pathophysiology01:21

Acute Pancreatitis II: Pathophysiology

The pathophysiology of acute pancreatitis centers on injury to pancreatic acinar cells, which initiates a cascade of harmful intracellular events.This injury leads to premature activation of trypsinogen to trypsin in the pancreas. Trypsin then activates other digestive enzymes, such as chymotrypsin, elastase, and phospholipase A2, which begin breaking down pancreatic tissue. The resulting autodigestion causes local inflammation, tissue swelling, hemorrhage, and fat necrosis.Injured acinar cells...
Chronic Pancreatitis I: Introduction01:25

Chronic Pancreatitis I: Introduction

Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Suprachoroidal Triamcinolone Plus Intravitreal Bevacizumab Versus Bevacizumab Alone for Diabetic Macular Edema in Pseudophakic Eyes: A randomized controlled trial.

Pakistan journal of medical sciences·2026
Same author

Structural and functional characterization of VapBC52 toxin-antitoxin system from Mycobacterium tuberculosis.

Nucleic acids research·2026
Same author

Risk factors for EBV reactivation and impact of graft composition following GVHD prophylaxis with rabbit ATG or PTCy.

Bone marrow transplantation·2026
Same author

Fenchone and cinnamyl acetate attenuate L-NAME-induced hypertension via modulation of vascular dysfunction, oxidative stress, and renal injury: An integrated network pharmacology, molecular docking, and ADMET study.

European journal of pharmacology·2026
Same author

Efficacy and Safety of a Tacrolimus Lipid Suspension Enema in Mild-to-Moderate Ulcerative Colitis: A Multicenter, Prospective, Double-Blind, Phase II Randomized Controlled Trial.

Clinical therapeutics·2026
Same author

Early Initiation of Defibrotide is Associated With Better Survival in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease in Adults: Experience From Two Canadian Centers.

Transplantation and cellular therapy·2026

Related Experiment Video

Updated: Jul 15, 2026

Sodium Taurocholate Induced Severe Acute Pancreatitis in C57BL/6 Mice
06:35

Sodium Taurocholate Induced Severe Acute Pancreatitis in C57BL/6 Mice

Published on: June 28, 2021

Ezetimibe-induced acute pancreatitis.

Imran Ahmad1, Edward Ruby, Harris Usman

  • 1Mercy Fitzgerald Hospital, Darby, PA, USA. iahmadmd@yahoo.com

Southern Medical Journal
|April 27, 2007
PubMed
Summary

Ezetimibe effectively lowers cholesterol by inhibiting intestinal absorption. Despite its widespread use since 2002, no documented cases link ezetimibe to pancreatitis, suggesting a favorable safety profile for this lipid-lowering agent.

More Related Videos

Establishment of a Mouse Severe Acute Pancreatitis Model using Retrograde Injection of Sodium Taurocholate into the Biliopancreatic Duct
07:10

Establishment of a Mouse Severe Acute Pancreatitis Model using Retrograde Injection of Sodium Taurocholate into the Biliopancreatic Duct

Published on: April 1, 2022

Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection
07:38

Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection

Published on: May 10, 2024

Related Experiment Videos

Last Updated: Jul 15, 2026

Sodium Taurocholate Induced Severe Acute Pancreatitis in C57BL/6 Mice
06:35

Sodium Taurocholate Induced Severe Acute Pancreatitis in C57BL/6 Mice

Published on: June 28, 2021

Establishment of a Mouse Severe Acute Pancreatitis Model using Retrograde Injection of Sodium Taurocholate into the Biliopancreatic Duct
07:10

Establishment of a Mouse Severe Acute Pancreatitis Model using Retrograde Injection of Sodium Taurocholate into the Biliopancreatic Duct

Published on: April 1, 2022

Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection
07:38

Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection

Published on: May 10, 2024

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Cardiovascular Medicine

Background:

  • Ezetimibe is a cholesterol absorption inhibitor used to treat hypercholesterolemia.
  • It functions by reducing the uptake of dietary and biliary cholesterol in the intestine.
  • Ezetimibe is prescribed as monotherapy or in combination with other lipid-lowering drugs.

Observation:

  • The U.S. Food and Drug Administration (FDA) approved ezetimibe in 2002.
  • Extensive clinical use and post-marketing surveillance have followed its approval.
  • A review of medical literature has been conducted to identify adverse events associated with ezetimibe.

Findings:

  • No reported cases of ezetimibe-induced pancreatitis have been identified in the literature.
  • This suggests a lack of association between ezetimibe and the development of pancreatitis.
  • The safety profile of ezetimibe regarding pancreatitis appears to be favorable.

Implications:

  • The absence of pancreatitis cases supports the established safety of ezetimibe in managing hypercholesterolemia.
  • Clinicians can be reassured regarding this specific adverse event when prescribing ezetimibe.
  • Further pharmacovigilance may continue to monitor for rare adverse events, but pancreatitis is not a current concern.